Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2010 - 2026)

Pharma-Bio Serv's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $11.5 million for Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $11.5 million, down 17.29% year-over-year; the trailing twelve-month figure through Apr 2026 was $52.3 million (down 16.46% YoY), and the FY2025 annual result was $13.7 million, down 16.2% from the prior year.
• Liabilities and Shareholders Equity came in at $11.5 million for Q2 2026 at Pharma-Bio Serv, down from $13.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.9 million in Q1 2023 to a low of $11.5 million in Q2 2026.
• A 5-year average of $17.6 million and a median of $18.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 28.91% in 2022 and increased 3.74% in 2023, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $20.7 million in 2022, then retreated by 3.63% to $19.9 million in 2023, then fell by 18.14% to $16.3 million in 2024, then decreased by 16.2% to $13.7 million in 2025, then decreased by 15.77% to $11.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $11.5 million (Q2 2026), $13.5 million (Q1 2026), and $13.7 million (Q4 2025), per Business Quant data.